Prodrug and covalent linker strategies for the solubilization of dual-action antioxidants/iron chelators

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 22, 2002, Pages 3297-3300

  Bebbington, David ^a,b   Dawson, Claire E ^a   Gaur, Suneel ^a   Spencer, John ^a  

^a Vernalis PLC   (United Kingdom)

^b James Black Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; DEFERIPRONE; IRON CHELATING AGENT; MACROGOL DERIVATIVE; PRODRUG; SCAVENGER; WATER; BUTYLCRESOL; CROSS LINKING REAGENT; PYRIDONE DERIVATIVE;

AMINATION; ARTICLE; COVALENT BOND; DRUG SOLUBILITY; DRUG SYNTHESIS; HYBRID; HYDROLYSIS; MOLECULE; SOLUBILIZATION; ANIMAL; CHEMISTRY; METABOLISM; PLASMA; RAT; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIOXIDANTS; BUTYLATED HYDROXYTOLUENE; CROSS-LINKING REAGENTS; HYDROLYSIS; IRON CHELATING AGENTS; PLASMA; POLYETHYLENE GLYCOLS; PRODRUGS; PYRIDONES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037131748     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00698-4     Document Type: Article

References (20)

1. (a) Marciniak G., Petty M.A. Drugs Future. 21:1996;1037 (b) Butterfield D.A., Howard B.J., LaFontaine M.A. Curr. Med. Chem. 8:2001;815 (c) Pitchumoni S.S., Doraiswamy P.M. J. Am. Geriatrics Soc. 46:1998;1566.
2. (a) Hunter, A.J.; Green, A.R.; Cross A.J. Trends Pharmacol. Sci. 1995, 16, 123.
3. (b) Norris, J. W.; Hachinski, V. Eds.; Stroke Prevention; Oxford, 1999.
4. (c) Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J. New Engl. J. Med. 1997, 336, 1216
5. Clark, W.M.; Rinker, L.G.; Lessov, N.S.; Lowery, S.L.; Cipolla, M.J. Stroke 2001, 32, 1000.
6. Bebbington, D.; Monck, N.J.T.; Gaur, S.; Palmer, A.M.; Benwell, K.; Harvey, V.; Malcolm, C.S.; Porter, R.H.P. J. Med. Chem. 2000, 43. 2779.
7. (b) See, for example: EP 1006108A1; Chem. Abstr. 2000, 133, 17385. WO 9923075; Chem. Abstr. 1999, 130, 338022.
8. (b) See, for example: EP 1006108A1; Chem. Abstr. 2000, 133, 17385. WO 9923075; Chem. Abstr. 1999, 130, 338022.
9. Malcolm C.S., Benwell K.R., Lamb H., Bebbington D., Porter R.H.P. Free Radical Biol. Med. 28:2000;102.
10. Review: Wermuth, C. G. In The Practice of Medicinal Chemistry; Wermuth, C. G., Ed.; Academic: London, 1996; p 755.
11. Review: Wermuth, C. G.; Gaignault, J.; Marchandeau, C. In The Practice of Medicinal Chemistry; Wermuth, C. G., Ed.; Academic: London, 1996; p 671.
12. See, for example: WO9807713; Chem. Abstr. 1998, 128, 217533. WO9324476; Chem. Abstr. 1993, 120, 144136.
13. See, for example: WO9807713; Chem. Abstr. 1998, 128, 217533. WO9324476; Chem. Abstr. 1993, 120, 144136.
14. (a) Rai B.L., Dekhordi L.S., Khodr H., Jin Y., Liu Z., Hider R.C. J. Med. Chem. 41:1998;3347 (b) Dobbin P.S., Hider R.C., Hall A.D., Taylor P.D., Sarpong P., Poter J.B., Xiao G., van der Helm D. J. Med. Chem. 36:1993;2448.
15. Hansen M.M., Riggs J.R. Tetrahedron Lett. 39:1998;2705.
16. Full experimental details for the synthesis of 3-13 and analytical data are provided in ref 3(b).
17. (a) Takata J., Ito S., Karube Y., Nagata Y., Matsushima Y. Biol. Pharm. Bull. 20:1997;204 (b) Takata J., Karube Y., Nagata Y., Matsushima Y. J. Pharm. Sci. 84:1995;96.
18. Determination of water solubility. To 5 mg of the test compound in a clear glass vial was added 0.25 mL HPLC grade water and the vial was shaken vigorously for 1 h at room temperature. The sample was viewed by visual inspection to determine whether any particles of compound remained and also the sample was viewed between crossed polarising filters in front of a light source. If undissolved compound remained then a second portion of 0.25 mL HPLC grade water was added and the process repeated until complete dissolution was apparent. Although a more accurate determination of water solubility could be obtained from analysing aqueous solutions by HPLC, the chromatograms obtained from these molecules are characterised by broad, asymmetric peak shapes due to the iron chelating ability of these molecules.
19. . We did not attempt to derivatize the phenolic group in 14, although there is precedent for prodrug formation at hindered phenols as in the related anaesthetic 2,6-diisopropylphenol, Propofol. See: Trapani G., Latrofa A., Franco M., Lopedota A. Maciocco, Liso, G. Int. J. Pharm. 175:1998;195.
20. (a) . The investigation of dual action molecules for neuroprotection is a very active field of research at present: Jarrott B., Callaway J.K., Jackson W.R., Beart P.M. Drug Dev. Res. 46:1999;261 (b) Ohkawa S., Fukatsu K., Miki S., Hashimoto T., Sakamoto J., Doi T., Nagai Y., Aono T. J. Med. Chem. 40:1997;559 (c) Chabrier P.E., Auguet A., Spinnewyn B., Auvin S., Cornet S., Demerlé-Pallardy C., Guilmard-Favre C., Marin J.-G., Pignol B., Gillard Roubert V., Roussillot-Charnet C., Schulz J., Viossat I., Bigg D., Moncada S. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10824 (d) Giblin G.M.P., Box P.C., Campbell I.C., Hancock A.P., Roomans S., Mills G.I., Molloy C., Tranter G.E., Walker A.L., Doctrow S.R., Huffman K., Malfroy B. Bioorg. Med. Chem. Lett. 11:2001;1367 (e) Naughton D.P., Grootveld M. Bioorg. Med. Chem. Lett. 11:2001;2573.